Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Recruiting

Phase 3

AnifrolumabPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Sponsor:

AstraZeneca

Code:

NCT05138133

Conditions

Lupus Nephritis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Anifrolumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-04-25.